Regeneron (REGN) Tops Q1 EPS by $1.45
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Regeneron Reports First Quarter 2022 Financial and Operating Results
May 4, 2022 6:30 AM EDTTARRYTOWN, N.Y., May 4, 2022 /PRNewswire/ --
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV®(a)(b), revenues increased 25%First quarter 2022 EYLEA® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021First quarter 2022 Dupixent® global net sales(c)(recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021First quarter 2022 GAAP diluted EPS of $8.61; non-GAAP diluted EPS(a) of $11.49Dupixent approved in EU for children aged 611 years with severe asthma; FDA priority review... More